Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials
Hagins, D, Orkin, C, Daar, ES, Mills, A, Brinson, C, DeJesus, E, Post, FA, Morales-Ramirez, J, Thompson, M, Osiyemi, O, Rashbaum, B, Stellbrink, H-J, Martorell, C, Liu, H, Liu, Y-P, Porter, D, CollinsLanguage:
english
Journal:
HIV Medicine
DOI:
10.1111/hiv.12664
Date:
August, 2018
File:
PDF, 238 KB
english, 2018